FY2027 EPS Estimates for MannKind Lowered by HC Wainwright

MannKind Corporation (NASDAQ:MNKD) – Investment analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for shares of MannKind in a research report issued to clients and investors on Thursday, April 23rd. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will post earnings per share of $0.03 for the year, down from their previous estimate of $0.05. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for MannKind’s current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for MannKind’s FY2029 earnings at $0.16 EPS and FY2030 earnings at $0.54 EPS.

Several other equities research analysts also recently commented on the company. Wedbush dropped their target price on MannKind from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Thursday, March 5th. Weiss Ratings downgraded MannKind from a “hold (c)” rating to a “sell (d+)” rating in a report on Monday, March 2nd. Mizuho dropped their price objective on MannKind from $10.00 to $8.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. Wells Fargo & Company dropped their price objective on MannKind from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Finally, Wall Street Zen downgraded MannKind from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.56.

MannKind Stock Performance

Shares of NASDAQ:MNKD opened at $2.70 on Friday. The company has a market cap of $833.76 million, a P/E ratio of 135.07 and a beta of 1.04. MannKind has a one year low of $2.23 and a one year high of $6.51. The business’s 50-day simple moving average is $3.09 and its 200 day simple moving average is $4.71.

MannKind (NASDAQ:MNKD) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.04). The company had revenue of $111.96 million for the quarter, compared to analysts’ expectations of $99.85 million. MannKind had a net margin of 1.68% and a negative return on equity of 11.21%. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.03 earnings per share.

Insider Transactions at MannKind

In other MannKind news, CEO Michael Castagna acquired 100,000 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were bought at an average cost of $2.59 per share, for a total transaction of $259,000.00. Following the acquisition, the chief executive officer directly owned 2,575,911 shares of the company’s stock, valued at $6,671,609.49. This trade represents a 4.04% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On MannKind

Several hedge funds and other institutional investors have recently bought and sold shares of MNKD. Krilogy Financial LLC purchased a new stake in MannKind during the 1st quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of MannKind by 108.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,927 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of MannKind in the 4th quarter valued at approximately $45,000. Discipline Wealth Solutions LLC bought a new stake in shares of MannKind in the 1st quarter valued at approximately $45,000. Finally, Burkett Financial Services LLC bought a new stake in shares of MannKind in the 4th quarter valued at approximately $59,000. 49.55% of the stock is currently owned by hedge funds and other institutional investors.

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.